Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355088 | 1.00 | CAMK2A (0.46) | CAMK2ALMNASLC22A6NFKB1TSHR | |
| SCHEMBL15153687 | 0.93 | LMNA (0.50) | CAMK2ALMNASLC22A6NFKB1TSHR | |
| SCHEMBL2473072 | 0.93 | LMNA (0.50) | CAMK2ALMNASLC22A6NFKB1TSHR | |
| SCHEMBL3100157 | 0.91 | LMNA (0.52) | LMNASLC22A6NFKB1TSHRPMP22 | |
| SCHEMBL10944728 | 0.91 | LMNA (0.52) | LMNASLC22A6NFKB1TSHRPMP22 | |
| Adipic Acid SCHEMBL7050293 | 0.91 | LMNA (0.52) | LMNASLC22A6NFKB1TSHRPMP22 | |
| SCHEMBL11283608 | 0.91 | LMNA (0.52) | LMNASLC22A6NFKB1TSHRPMP22 | |
| SCHEMBL11279244 | 0.91 | LMNA (0.52) | LMNASLC22A6NFKB1TSHRPMP22 | |
| Adipic Acid SCHEMBL9319144 | 0.89 | FFAR1 (0.54) | CAMK2ALMNASLC22A6NFKB1TSHR | |
| Adipic Acid SCHEMBL28446848 | 0.87 | LMNA (0.61) | CAMK2ALMNASLC22A6NFKB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2006052950-A1 | 5,6,7-TRIHYDROXYHEPTANOIC ACID AND ANALOGS FOR THE TREATMENT OF OCULAR DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVE AND ANGIOGENIC RESPONSES | ALCON, INC. (CH) | 2006-05-18 | — | — | WO | disclosed |
| US-20060099248-A1 | 5,6,7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | ALCON, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20060099248-A1 | 5,6,7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | ALCON, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20060099248-A1 | 5,6,7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | ALCON, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20060058375-A1 | Method of treating dry eye disorders and uveitis | ALCON, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060058375-A1 | Method of treating dry eye disorders and uveitis | ALCON, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2005112905-A1 | METHOD OF TREATING DRY EYE DISORDERS AND UVEITIS | ALCON, INC. (CH) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005112905-A1 | METHOD OF TREATING DRY EYE DISORDERS AND UVEITIS | ALCON, INC. (CH) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256189-A1 | Method of treating dry eye disorders and uveitis | ALCON, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050256189-A1 | Method of treating dry eye disorders and uveitis | ALCON, INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256189-A1 | Method of treating dry eye disorders and uveitis | HRH2, FAAH2, FAAH | CAMK2A 2372/4885LMNA 4504/4885SLC22A6 1778/4885 |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-20060099248-A1 | 5,6,7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | HPGDS, ADCYAP1R1, VEGFA | CAMK2A 2612/4885LMNA 2852/4885SLC22A6 1953/4885 |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-20060058375-A1 | Method of treating dry eye disorders and uveitis | HRH2, FAAH2, FAAH | CAMK2A 2372/4885LMNA 4504/4885SLC22A6 1778/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | CAMK2A 1440/4885LMNA 1219/4885SLC22A6 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.